WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2006/088741    International Application No.:    PCT/US2006/004789
Publication Date: 24.08.2006 International Filing Date: 10.02.2006
G01N 33/86 (2006.01), A61K 38/36 (2006.01), A61K 47/48 (2006.01), A61P 7/04 (2006.01)
Applicants: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS [US/US]; 352 HENRY ADMINISTRATION BUILDING, 506 Wright, Urbana, Illinois 61801 (US) (For All Designated States Except US).
MORRISSEY, James, Henry [US/US]; (US) (For US Only).
WATERS, Emily, Kerestes [US/US]; (US) (For US Only)
Inventors: MORRISSEY, James, Henry; (US).
WATERS, Emily, Kerestes; (US)
Agent: RAUCH, Paul, E.; Evan Law Group LLC, 600 West Jackson, Suite 625, Chicago, Illinois 60661 (US)
Priority Data:
60/653,695 16.02.2005 US
Abstract: front page image
(EN)A thromboplastin reagent comprises: (i) activated sTF, (ii) a metal-chelating lipid, (iii) a metal ion, and (iv) a phospholipid. Activated sTF preferably includes the extracellular domain of TF and an oligohistidine moiety having at least 2 histidine residues, more preferably 2-10 histidine residues. Preferably, the histidine residues are consecutive. Attaching a metal binding domain, such as an oligohistidine tag, to the C-terminus of sTF allows the protein to bind to phospholipid vesicles that contain metal -chelating lipid. Metal complexes of this activated sTF and metal-chelating lipids have all of the desirable expression, handling, and solubility characteristics of sTF, and exhibit procoagulant activities in plasma clotting tests that are comparable to relipidated rTF. In addition, it was discovered that, under some circumstances, Ni-lipids are themselves procoagulant, even in the absence of activated sTF. Further studies indicated that Ni-lipids are potent activators of the contact pathway of blood clotting.
(FR)Un réactif de thromboplastine renferme : (i) sTF activé, (ii) un lipide chélateur métallique, (iii) un ion métallique et (iv) un phospholipide.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)